The day wishes for the heart and lungs of the sick and injured are in, and the medical profession is getting ready to offer some new therapies.
Heart-Lung Therapies, the latest addition to the list of possible treatments, has been developed by a team at University of Melbourne, the University of Queensland and the Australian National University.
They hope it will help patients who suffer from respiratory problems, chronic obstructive pulmonary disease (COPD), or chronic obstructor disease (COVID).
It will not treat everything, but it will certainly provide some relief from the pain.
“The goal of our program is to alleviate some of the pain, and then we can go about things that can be very effective for people who have COPD,” Dr Michael Gazzaniga, who heads up the research group at the University’s School of Health, said.
The new therapies are being developed by an international team, and are based on a different model to the current standard of chest physiotherapies.
Instead of relying on breathing, the patients are placed in a chamber, and a pump pumps air into the lungs.
This causes air to be released through the nose into the airways.
The pump is then turned on to deliver the correct amount of oxygen to the lungs, which can be controlled by breathing.
The air is then exhaled through the mouth to the face.
Dr Gazzansi said there was an “unusual” amount of air in the chamber at any one time, which is why the air-in-the-nose therapy is different from what was used before.
In other words, there is a lot more oxygen going into the system.
In addition to delivering oxygen, the system is also used to measure the pressure in the airway, which helps with breathing.
There is a small amount of blood in the chambers, which also helps the lungs work better, he said.
There are also sensors in the devices, which measure the intensity of the oxygen delivery.
If it is too high, the patient can be given a breathing aid, such as a mask or mask fitted with an electronic device.
In this way, patients have some control over the amount of breathing air they are given.
The patients can also take the device and use it as a hand, or use it in a massage to help them relax.
This may seem counter-intuitive, but the devices are not only used to deliver oxygen, but also to monitor the oxygen level in the lungs as well.
Dr Peter Williams, an associate professor of internal medicine at the College of Medical Medicine at the Australian University of Sydney, said that if the devices worked as advertised, it would be a huge improvement to the lives of people with COPD.
But he cautioned that they were still far from being suitable for everyone.
“We are talking about an older population, we’re talking about a very large group of people,” Dr Williams said.
“There are still a number of people in the world who have not been properly evaluated for their COVID-19 status, and we can’t offer a therapy that can help them all.”
In Australia, the first trials are due to start in 2019.
There have been some concerns about the effectiveness of the devices.
The ABC has been told by a leading medical journal that there was no research into the devices’ safety.
In an editorial, the journal’s editor in chief Dr David McBride wrote: “The use of oxygen in a chest physiostomy is an innovative and potentially lifesaving therapeutic option for some patients with COPE, but no research has been conducted to confirm its effectiveness.”
Dr Williams also raised concerns about a possible lack of evidence that the device would help people with COVID.
He said that for now, he had not seen any scientific evidence that showed it would work.
“If it is shown to be effective in helping people with asthma, then there will be some potential for it to work in some other asthma patients as well,” Dr Gaffas said.
While there was some concern about the devices safety, Dr Gaffe said he had seen no evidence that it had caused any adverse side effects.
Dr Williams believes the devices could be very useful for people with heart problems.
He noted that they could help with the symptoms of COPD, but that the main concern was the increased risk of infection.
He is concerned about potential infections from the device, as it could potentially expose people to the virus.
“Aspirin, aspirin tablets, they are all the same thing.
They are all very similar, they’re all effective, but they are very different in that you’re not going to get all the benefits,” he said, noting that a common side effect of the device was that patients felt more tired.
Dr Dermot Kelly is also worried about the potential side effects of the new technology.
“I would say it is a real question mark